Left ventricular regional dysfunction using cardiac magnetic resonance imaging in rheumatoid arthritis patients without cardiac symptoms: Comparison between methotrexate and biologics treatment groups

Journal of Rheumatology

Volumn 41, Issue 7, 2014, Pages 1560-1562

  Kobayashi, Yasuyuki ^a   Kobayashi, Hitomi ^b   Hirano, Masaharu ^c   Giles, Jon T ^d  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Itabashi Chuo Medical Center   (Japan)

^c Tokyo Medical University School of Medicine   (Japan)

^d Division of Rheumatology Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHOTREXATE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ADULT; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; LETTER; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT INDICATION; AGED; ARTHRITIS, RHEUMATOID; COMPLICATION; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; MIDDLE AGED; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84903695774     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121363     Document Type: Letter

References (10)

1. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303-7. (Pubitemid 36314415)
2. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis. Arthritis Rheum 2005;52:722-32.
3. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005;52:402-11. (Pubitemid 40220344)
4. Castillo E, Lima JA, Bluemke DA. Regional myocardial function: advances in MR imaging and analysis. Radiographics 2003;23:S127-40.
5. Schuster A, Kutty S, Padiyath A, Parish V, Gribben P, Danford DA, et al. Cardiovascular magnetic resonance myocardial feature tracking detects quantitative wall motion during dobutamine stress. J Cardiovasc Magn Reson 2011;13:58.
6. Schuster A, Paul M, Bettencourt N, Morton G, Chiribiri A, Ishida M, et al. Cardiovascular magnetic resonance myocardial feature tracking for quantitative viability assessment in ischemic cardiomyopathy. Int J Cardiol 2013;166:413-20.
7. Kerekes G, Soltesz P, Nurmohamed MT, Gonzalez-Gay MA, Turiel M, Vegh E, et al. Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat Rev Rheumatol 2012;8:224-34.
8. Atzeni F, Turiel M, Caporali R, Cavagna L, Tomasoni L, Sitia S, et al. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun Rev 2010;9:835-9.
9. Kobayashi Y, Giles JT, Hirano M, Yokoe I, Nakajima Y, Bathon JM, et al. Assessment of cardiac involvement in rheumatoid arthritis using a comprehensive cardiac magnetic resonance approach: association of myocardial abnormalities with disease activity. Arthritis Res Ther 2010;12:R171.
10. Avouac J, Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Pharmacother 2008; 9:1121-8. (Pubitemid 351721750)